Vaizensell to Present Preclinical Results of Glioblastoma Pipeline 'VC302' at European Association for Cancer Research
Joint Development of 'VC302' with Therabest
Poster Presentation at EACR
Vaizensell, a company specializing in new drug development, announced on June 8 that it will present a poster on the preclinical research results of its glioblastoma pipeline 'VC302', which is being co-developed with Therabest, at the European Association for Cancer Research (EACR 2026).
The European Association for Cancer Research (EACR), established in 1968, is the largest international academic society in European cancer research, with over 12,000 members from more than 100 countries. This year, the event is being held in Budapest, Hungary, from June 8 to 11 (local time).
At EACR 2026, Vaizensell will present a poster on the preclinical study results of the glioblastoma pipeline 'VC302', which is under joint development with Therabest.
Glioblastoma is the most common and aggressive malignant brain tumor, characterized by its rapid growth and metastasis, resulting in very low survival rates and high recurrence rates despite standard treatments. Additionally, the presence of the blood-brain barrier (BBB), which blocks foreign substances in the brain, makes it difficult for drugs to reach tumor cells inside the brain.
The poster presented by Vaizensell at this year's EACR features the preclinical research results of a next-generation GD2-targeted iPSC-derived CAR-NK cell therapy, developed using a triple-enhanced immune function platform designed to overcome the challenges of glioblastoma treatment by simultaneously improving tumor migration ability, in vivo persistence, and immune evasion. The therapy incorporates triple genetic modifications to enhance in vivo survival and tumor-seeking capability, as well as to reduce immune rejection, aiming to improve anticancer efficacy.
In in vitro experiments, 'VC302' demonstrated up to five times greater tumor-targeting ability compared to conventional NK cells. It also showed long-term survival while evading immune system attacks and exhibited more than fivefold higher survival rates than existing CAR-NK cells even without external cytokines that aid cell survival.
In a glioblastoma mouse model, administration of 'VC302' via intracerebroventricular (ICV) injection resulted in superior antitumor effects compared to the NK cell therapy control group. Notably, all six mice in the 'VC302' group achieved 100% complete remission (CR), with total tumor disappearance, and maintained this complete remission state for an extended period, confirming strong and sustained anticancer efficacy.
Ki Pyungseok, CEO of Vaizensell, stated, "This study demonstrates that 'VC302' can simultaneously address the issues of in vivo persistence, tumor migration, and immune rejection that have been cited as limitations of existing therapies. We will continue to advance R&D with the goal of initiating Phase 1 clinical trials next year and strive to establish 'VC302' as a new therapeutic option for glioblastoma in both domestic and international markets."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, 'VC302' by Vaizensell is designed as an off-the-shelf product, enabling effective cost reduction through mass production and allowing for immediate treatment of critically ill patients. Last year, the company also presented a poster on joint research results with Professor Jihoon Pi's team at Seoul National University Hospital at the European Society for Medical Oncology (ESMO).
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.